OptimizeRx (NASDAQ:OPRX) Price Target Raised to $11.00

OptimizeRx (NASDAQ:OPRX) had its price objective increased by B. Riley Financial from $10.00 to $11.00 in a research report issued on Tuesday, Marketbeat reports. The firm currently has a “buy” rating on the stock. B. Riley Financial’s price target suggests a potential upside of 37.59% from the company’s previous close.

Several other equities analysts have also recently commented on the stock. Citigroup reaffirmed a “market outperform” rating on shares of OptimizeRx in a research report on Friday, August 14th. UBS Group set a $11.00 price target on OptimizeRx in a research note on Friday, August 14th. Stifel Nicolaus set a $12.00 price objective on shares of OptimizeRx in a research note on Thursday, August 13th. Wall Street Zen downgraded shares of OptimizeRx from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 20th. Finally, Weiss Ratings upgraded OptimizeRx from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, August 25th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $11.57.

OptimizeRx Stock Up 2.4%

NASDAQ:OPRX traded up $0.18 during mid-day trading on Tuesday, hitting $8.00. The company had a trading volume of 35,804 shares, compared to its average volume of 382,236. The business has a fifty day simple moving average of $7.40 and a 200-day simple moving average of $6.45. The firm has a market capitalization of $150.63 million, a price-to-earnings ratio of 34.81 and a beta of 1.09. OptimizeRx has a 1 year low of $4.54 and a 1 year high of $22.25. The company has a current ratio of 5.58, a quick ratio of 5.58 and a debt-to-equity ratio of 0.14.

OptimizeRx (NASDAQ:OPRX) last posted its quarterly earnings data on Wednesday, August 12th. The company reported $0.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.05. OptimizeRx had a net margin of 4.66% and a return on equity of 9.44%. The company had revenue of $20.50 million for the quarter, compared to analyst estimates of $20.20 million. Equities analysts forecast that OptimizeRx will post 0.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On OptimizeRx

Large investors have recently added to or reduced their stakes in the business. Rice Hall James & Associates LLC lifted its stake in shares of OptimizeRx by 1.9% during the first quarter. Rice Hall James & Associates LLC now owns 601,921 shares of the company’s stock valued at $3,780,000 after buying an additional 11,247 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of OptimizeRx by 22.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 563,570 shares of the company’s stock worth $3,540,000 after acquiring an additional 102,661 shares during the period. Next Century Growth Investors LLC grew its holdings in OptimizeRx by 139.8% in the fourth quarter. Next Century Growth Investors LLC now owns 505,407 shares of the company’s stock valued at $6,196,000 after purchasing an additional 294,688 shares during the period. AWM Investment Company Inc. acquired a new position in OptimizeRx during the second quarter worth approximately $1,375,000. Finally, Renaissance Technologies LLC raised its stake in OptimizeRx by 633.2% during the first quarter. Renaissance Technologies LLC now owns 216,856 shares of the company’s stock worth $1,362,000 after purchasing an additional 187,278 shares during the period. 76.47% of the stock is owned by institutional investors and hedge funds.

OptimizeRx Company Profile

OptimizeRx Corporation (NASDAQ: OPRX) is a digital health company that provides technology and data-driven engagement solutions for life sciences companies, healthcare providers and patients. Its platform is designed to support communication across the healthcare journey, helping pharmaceutical and biotechnology companies connect with clinicians and patients through digital channels.

The company’s solutions include point-of-care messaging, patient savings and financial assistance programs, medication adherence and support services, and analytics and audience-engagement tools.